US Patent
US9085553 — LFA-1 inhibitor and methods of preparation and polymorph thereof
Formulation · Assigned to Sarcode Bioscience Inc · Expires 2033-07-25 · 7y remaining
Vulnerability score
42/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent discloses methods of preparation and purification of a compound, formulations, and uses thereof in treating LFA-1 mediated diseases.
USPTO Abstract
Methods of preparation and purification of a compound of Formula I, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed.
Drugs covered by this patent
- Xiidra (LIFITEGRAST) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.